60 DEGREES PHARMACEUTICALS, INC. (SXTP): Nasdaq/NYSE listing notice — Nasdaq notifies 60 Degrees Pharmaceuticals of delisting for bid price rule violation

60 DEGREES PHARMACEUTICALS, INC.

Nasdaq determined common stock failed $1.00 minimum bid price for 30 consecutive business days.
Company ineligible for compliance period due to 1-for-5 reverse stock split on Feb 24, 2025.
Warrants also subject to delisting under Nasdaq Listing Rule 5560(a).
Company paid $20,000 hearing fee and appealed, staying suspension pending panel decision.
No assurance the Nasdaq Panel will grant continued listing.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

60 DEGREES PHARMACEUTICALS, INC. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv), 5560(a)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)(iv), 5560(a)

Exact text from the filing

January 20, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that Nasdaq staff has determined to delist the Company’s common stock and warrants from The Nasdaq Capital Market. As disclosed in the Notice, Nasdaq staff determined that the Company’s common stock failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days, in violation of Nasdaq Listing Rule 5550(a)(2). While companies are typically afforded a 180-calen

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

60 DEGREES PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-26-007330

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.